Physician profile
Martin L Evers
NPI 1366434110
$617.47
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $156.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $91.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $56.31 | 2019 | |
| Glaxosmithkline, LLC. | $53.88 | 2019 | |
| Merck Sharp & Dohme LLC | $43.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.76 | 2019 | |
| Amgen INC. | $30.14 | 2019 | |
| Lilly USA, LLC | $27.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.37 | 2019 | |
| Shire North American Group INC | $15.65 | 2019 | |
| Amarin Pharma, INC. | $14.82 | 2019 | |
| Pfizer INC. | $12.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Evers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.